Chiasma Announces Publication of Pivotal Data from the Phase 3 CHIASMA OPTIMAL Clinical Trial in the Journal of Clinical Endocrinology & Metabolism

    NEXT STORY
    TRACON Pharmaceuticals Announces FDA Clearance of ENVASARC Pivotal Trial
    PREV STORY
    The World’s Pharmaceutical Drug Delivery Industry, 2025 – Growth in the Biologics Market is Driving Opportunities
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2018

    author_avatar
    NASDAQ Market News

    Aptevo Therapeutics Announces New IXINITY Supply Available May 2017

    SEATTLE, March 15, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company ...

    author_avatar
    NASDAQ Market News

    Admera Health Launches New Tests for Cancer Supportive Care and Liquid Biopsy, Now Provides a Comprehensive Portfolio of Oncology Products

    SOUTH PLAINFIELD, N.J., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Today, Admera Health (www.admerahealth.com) announced ...

    author_avatar
    NASDAQ Market News